|
FOXO3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.45850000041892E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.46980000001762E-06 |
| Normal-vs-Stage2 |
2.98130000020436E-07 |
| Normal-vs-Stage3 |
9.42029999562166E-08 |
| Normal-vs-Stage4 |
1.38679999994729E-06 |
| Stage1-vs-Stage2 |
7.323900E-02 |
| Stage1-vs-Stage3 |
1.420440E-02 |
| Stage1-vs-Stage4 |
3.254400E-01 |
| Stage2-vs-Stage3 |
9.895000E-01 |
| Stage2-vs-Stage4 |
4.557200E-01 |
| Stage3-vs-Stage4 |
3.823000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.15980000003901E-06 |
| Normal-vs-AfricanAmerican |
3.904700E-03 |
| Normal-vs-Asian |
2.94680000001435E-06 |
| Caucasian-vs-AfricanAmerican |
1.469820E-01 |
| Caucasian-vs-Asian |
9.019400E-01 |
| AfricanAmerican-vs-Asian |
2.263200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.68569999975988E-07 |
| Normal-vs-Female |
1.09079999999206E-06 |
| Male-vs-Female |
6.557000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96802999999912E-05 |
| Normal-vs-Age(41-60Yrs) |
8.07609999986525E-07 |
| Normal-vs-Age(61-80Yrs) |
5.69270000028155E-08 |
| Normal-vs-Age(81-100Yrs) |
7.70920000000563E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.454150E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.895900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.303600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.098570E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.228800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.995400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.202100E-03 |
| Classical-VS-Follicular |
1.589930E-04 |
| Classical-VS-Other |
8.908600E-01 |
| Classical-VS-Normal |
2.37309999999713E-05 |
| Tall-VS-Follicular |
7.672400E-01 |
| Tall-VS-Other |
4.493200E-01 |
| Tall-VS-Normal |
1.68090000030041E-07 |
| Follicular-VS-Other |
2.494400E-01 |
| Follicular-VS-Normal |
3.69110000342232E-08 |
| Other-VS-Normal |
7.290000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.10150000010023E-07 |
| Normal-vs-N1 |
2.38240000000056E-05 |
| N0-vs-N1 |
2.573600E-01 |
|
|
